Navigation Links
Reminder - Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Systemic Lupus Erythematosus
Date:7/19/2009

ROCKVILLE, Maryland July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will host a conference call today at 8:15 AM Eastern to discuss the results from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 8364417.

This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS, Human Genome Sciences, BENLYSTA and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

[webcast]

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has completed delivery of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to FDA's approval of the Company's Biologics License Application for ABthrax. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reminders Boost Mammography Appointments
2. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
3. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
4. Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients
5. Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
6. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
7. There is No Place Like CareMinders Home Care and the Dedication and Commitment of the Owners
8. Understand Colon Cancer with MyBiopsy.Org; Schedule a Screening Test at MyHealthTestReminder.Org
9. New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use
10. Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Societys Midwinter Meeting
11. Recently Reported Childhood Deaths from Influenza Are a Stark Reminder to Vaccinate Now
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... NC (PRWEB) , ... December 08, 2016 , ... ... Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass media ... story movement gives people ongoing opportunities to share their unfortunate experiences; such a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an Arizona-based ... the greater Phoenix metropolitan region, is announcing a charity event to provide support ... Homeless Youth Connection is to promote community awareness of the ongoing needs of ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated ... it is one of the early adopters completing EU-U.S. Privacy Shield Certification from the ... provide companies on both sides of the Atlantic with a mechanism to comply with ...
(Date:12/7/2016)... New Orleans, LA (PRWEB) , ... December 07, ... ... cosmetic technique used to treat wrinkles and deep lines by smoothing and tightening ... many minimally invasive techniques out there to address facial aging with very little ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)...  Economic growth in the United States will continue ... executives in their December 2016 Semiannual Economic Forecast. Expectations ... began in mid-2009, as indicated in the monthly ISM ... The manufacturing sector is optimistic about growth in 2017, ... and the non-manufacturing sector indicates that 14 of its ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... today that it will charge enterprise customers only when ... model disrupts the health and wellness sector, which typically ... Logo - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... platform  combines the power of technology with the empathy ...
Breaking Medicine Technology: